- Home
- BJRI vs ORIC Comparison
BJRI vs ORIC Comparison
Compare BJRI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- ORIC
- Stock Information
- Founded
- BJRI 1978
- ORIC 2014
- Country
- BJRI United States
- ORIC United States
- Employees
- BJRI N/A
- ORIC N/A
- Industry
- BJRI Restaurants
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- ORIC Health Care
- Exchange
- BJRI Nasdaq
- ORIC Nasdaq
- Market Cap
- BJRI 983.0M
- ORIC 938.2M
- IPO Year
- BJRI 1996
- ORIC 2020
- Fundamental
- Price
- BJRI $35.09
- ORIC $9.74
- Analyst Decision
- BJRI Hold
- ORIC Strong Buy
- Analyst Count
- BJRI 6
- ORIC 9
- Target Price
- BJRI $40.17
- ORIC $17.25
- AVG Volume (30 Days)
- BJRI 674.3K
- ORIC 1.3M
- Earning Date
- BJRI 07-31-2025
- ORIC 08-12-2025
- Dividend Yield
- BJRI N/A
- ORIC N/A
- EPS Growth
- BJRI N/A
- ORIC N/A
- EPS
- BJRI 1.17
- ORIC N/A
- Revenue
- BJRI $1,383,611,000.00
- ORIC N/A
- Revenue This Year
- BJRI $5.58
- ORIC N/A
- Revenue Next Year
- BJRI $2.93
- ORIC N/A
- P/E Ratio
- BJRI $30.06
- ORIC N/A
- Revenue Growth
- BJRI 4.07
- ORIC N/A
- 52 Week Low
- BJRI $27.89
- ORIC $3.90
- 52 Week High
- BJRI $47.02
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- BJRI 41.36
- ORIC 46.26
- Support Level
- BJRI $33.98
- ORIC $9.32
- Resistance Level
- BJRI $35.89
- ORIC $10.06
- Average True Range (ATR)
- BJRI 1.09
- ORIC 0.48
- MACD
- BJRI 0.31
- ORIC -0.02
- Stochastic Oscillator
- BJRI 65.05
- ORIC 57.46
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.